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Comorbidity and repeat admission to hospital for adverse
drug reactions in older adults: retrospective cohort study
Min Zhang, senior research fellow, C D’Arcy J Holman, professor of public health, Sylvie D Price, research
associate, Frank M Sanfilippo, research fellow, David B Preen, senior research fellow, Max K Bulsara,
associate professor of biostatistics
ABSTRACT
Objectives To identify factors that predict repeat
admission to hospital for adverse drug reactions (ADRs) in
older adults.
Design Population based retrospective cohort study.
Setting All public and private hospitals in Western
Australia.
Participants 28548 patients aged ≥60 years with an
admission for anADRduring1980-2000 followed for three
years using the Western Australian data linkage system.
Results 5056 (17.7%) patients had a repeat admission for
anADR. RepeatADRswereassociatedwith sex (hazard ratio
1.08, 95% confidence interval 1.02 to 1.15, for men), first
admission in 1995-9 (2.34, 2.00 to 2.73), length of hospital
stay (1.11, 1.05 to 1.18, for stays ≥14 days), and Charlson
comorbidity index (1.71, 1.46 to1.99, for score≥7); 60%of
comorbidities were recorded and taken into account in
analysis. In contrast, advancing age had no effect on repeat
ADRs. Comorbid congestive cardiac failure (1.56, 1.43 to
1.71), peripheral vascular disease (1.27, 1.09 to 1.48),
chronic pulmonary disease (1.61, 1.45 to 1.79),
rheumatological disease (1.65, 1.41 to 1.92), mild liver
disease (1.48, 1.05 to 2.07), moderate to severe liver
disease (1.85,1.18 to2.92),moderatediabetes (1.18,1.07
to1.30), diabeteswith chronic complications (1.91, 1.65 to
2.22), renal disease (1.93, 1.71 to 2.17), any malignancy
including lymphoma and leukaemia (1.87, 1.68 to 2.09),
and metastatic solid tumours (2.25, 1.92 to 2.64) were
strong predictive factors. Comorbidities requiring
continuing care predicted a reduced likelihood of repeat
hospital admissions for ADRs (cerebrovascular disease
0.85, 0.73 to 0.98; dementia 0.62, 0.49 to 0.78; paraplegia
0.73, 0.59 to 0.89).
ConclusionsComorbidity, but not advancing age, predicts
repeat admission for ADRs in older adults, especially
those with comorbidities often managed in the
community. Awareness of these predictors can help
clinicians to identify which older adults are at greater risk
of admission for ADRs and, therefore, who might benefit
from closer monitoring.
INTRODUCTION
Adverse drug reactions (ADRs) are a major public
health problem in older populations.1-3 In Western
countries, ADRs cause 3-6% of all hospital
admissions1-3 and are responsible for about 5-10% of
inpatient costs.4-6 We have previously reported that
repeat ADRs resulting in either hospital admission or
extended hospital stay increased at a greater rate than
first time ADRs in older adults from 1980-2003.
Furthermore, in Western Australia by 2003 over 30%
of all ADRs were repeat ADRs.7
Despite concerns that ADRs represent an important
medical problem in older people, the predictive factors
are still poorly understood. Older patients are vulner-
able to ADRs because of the multiple drugs that they
receive tomanage chronic diseases and also because of
Western Australia data linkage system 
(seven core datasets: hospital morbidity data system (hospital discharges), 
midwives’ notifications (data on pregnancy, labour, and birth), 
mental health services data (mental health admissions and outpatients), 
birth records (data from birth registry), death records (data from death registry), 
cancer registrations (cancer diagnoses), electoral roll registrations 
(provides random community samples)
Hospital morbidity data system
All hospital separations for all inpatients 
aged ≥60 years with ADR, 1980-2003
Data extracts included >800 000 
hospital separations
Non-residents and non-ADR 
hospital separations excluded
Patients with first time 
ADR only (n=23 492)
Patients with 
repeat ADR (n=5056)
Death registry
Death records for all inpatients with 
an ADR who died before 31 Dec 2003
Patients identified with 
≥1 ADR episodes (n=37 296) 
Patients followed up for 
<3 years excluded
Patients followed up for 
3 years (n=28 548)
Process of selecting patients for study from the Western Australia data linkage system
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changes in pharmacokinetics and
pharmacodynamics.8 9 Risk factors reported to be
independently associated with ADRs have included
advancing age, sex, comorbidity, multiple drug regi-
mens, inappropriate use of medication, alcohol intake,
poor cognitive function, and depression.4 10-15 There is
currently no consensus on which factors have the
greatest impact.
We conducted a retrospective cohort study based on
a state-wide population of patients to investigate
whether or not comorbid conditions, age and other
demographic factors, and drug category are associated
with a repeat admission for ADRs in people aged ≥60.
METHODS
Study setting and population
We used administrative data from all public and
private hospitals in Western Australia, a state with a
population of 2.09 million in 2007.16 The study
population consisted of all residents aged ≥60 with a
hospital admission related to an ADR identified
through the data linkage system. This system links
state-wide administrative health data at the individual
level using probabilistic matching of patients’ names
and other identifiers with clerical review of doubtful
matches. It includes links between seven core datasets,
of which the statutory death registry from 1969 and the
hospital morbidity data system (HMDS) from 1970
form the main parts.17 We used extracts of linked
hospital morbidity records and death records, with
encryption toprotect the identityof individualpatients.
The data were extracted in February 2005.
The hospital morbidity data system contained
information on encrypted patient identification and
episode number; age, sex, indigenous status, and
postcode; date of admission and date of separation
(that is, transfer, discharge, or inpatient death); inter-
national classification of diseases (ICD) codes for the
maindiagnosis andup to19additionaldiagnoses forup
to four external causes (E codes), and for the main
procedure and up to 10 additional procedures; type of
hospital attended (public, private, other), admission
type (emergency or elective), and payment classifica-
tion. We used ICD-9 for 1980-7,18 ICD-9-CM for
1988-June 1999,19 and ICD-10-AM from July 1999
onwards. 20 Data from the death records included
encrypted patient identification, age, sex, indigenous
status, primary cause of death, date of death, and
postcode. We extracted linked hospital and death
records for all patients aged ≥60 with an admission for
ADR in 1980-2003 in Western Australia. In an
assessment of the technical performance of the linkage
system in finding true matches between records, both
the proportion of invalid links (false positives) and of
missed links (false negatives) was estimated to be
0.11%.17
Definition of ADR and identification of patients
We included all ADRs that resulted in hospital
admission or that occurred while patients were in
hospital and extended the length of hospital stay. An
ADReventwas defined as any hospital separationwith
an ICD E code indicating that either the admission or
extended hospital stay was because of the adverse
effects ofdrugs,medicines, andbiological substances in
therapeutic use: E930–E949 (ICD-9 and ICD-9-CM)
or Y40–Y59 (ICD-10-AM). The codes included any
adverse effect caused by correct use of drugs,
medicines, or biological substances properly adminis-
tered in therapeutic or prophylactic doses, excluding
errors in the technique of administration of drugs,
intentional and unintentional overdose, and abuse of a
drug. Thus, our definition of ADRswas consistentwith
the more recent and clearer version: “An appreciably
harmful or unpleasant reaction, resulting from an
intervention related to the use of a medicinal product,
which predicts hazard from future administration and
warrants prevention or specific treatment, or alteration
of the dosage regimen, orwithdrawal of the product.”21
Table 1 | Drug categories (from ICD external cause codes) responsible for admission for first
time adverse drug reaction (ADR) in patients aged ≥60, Western Australia, 1980-2000
Drug category (as defined in ICD-10-AM) ICD-9/ICD-9-CM ICD-10-AM No (%) of patients
Systemic antibiotics* E930 Y40 2672 (9.4)
Other systemic anti-infectives/
antiparasitics
E931 Y41 430 (1.5)
Hormones (including synthetics and
antagonists)
E932 Y42 2174 (7.6)
Primarily systemic agents E933 Y43 2122 (7.4)
Agents primarily affecting blood
constituents
E934 Y44 2432 (8.5)
Analgesics/antipyretics/anti-
inflammatory drugs
E935 Y45 4694 (16.4)
Antiepileptics/antiparkinsonian drugs E936 Y46 1121 (3.9)
Sedatives, hypnotics, antianxiety drugs E937 Y47 406 (1.4)
Anaesthetics and therapeutic gases E938 Y48 414 (1.5)
Psychotropic drugs† E939 Y49 1534 (5.4)
Central nervous system stimulants E940 Y50 18 (0.1)
Drugs primarily affecting autonomic
nervous system‡
E941 Y51 476 (1.7)
Agents primarily affecting cardiovascular
system
E942 Y52 5576 (19.5)
Agents primarily affecting gastrointestinal
system
E943 Y53 252 (0.9)
Agents affecting water balance/minerals/
uric acid§
E944 Y54 2024 (7.1)
Agents affecting muscles/respiratory
system
E945 Y55 563 (2.0)
Topical agents affecting skin, eyes, ENT,
dental
E946 Y56 577 (2.0)
Other and unspecified drugs and
medicines
E947 Y57 982 (3.4)
Bacterial vaccines E948 Y58 16 (0.1)
Other and unspecified vaccines/
biologicals
E949 Y59 65 (0.2)
Total 28 548 (100.0)
ADR=adverse drug reaction; ICD=International Classification of Diseases; ENT=ear, nose, throat.
*Excludes antineoplastic antibiotics (E930.7) from ICD-9/ICD-9-CM (were added to primarily systemic agents,
which include antineoplastics).
†Excludes benzodiazepines (E939.4) from ICD-9/ICD-9-CM (were added to group sedatives, hypnotics,
antianxiety drugs, which includes benzodiazepines in ICD-10).
‡Excludes sympatholytics (E941.3) from ICD-9/ICD-9-CM (were added to agents primarily affecting
cardiovascular system, which include these in ICD-10).
§Excludes theophylline (E944.1) from ICD-9/ICD-9-CM (was added to agents affecting muscles/respiratory
system, which includes antiasthmatics).
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An ADR hospital episode was defined as a period of
continuous treatment for an ADR in one or more
hospitals, as a personmight havebeen transferred from
one hospital to another before they were discharged.
We checked all records for transfers between hospitals
and, where they existed, combined the admissions into
a single “episode” for analysis.
To ensure correct identification of first time ADRs,
we initially examined all admissions of the patients
dating back to 1970. We included 803 732 hospital
separations and audited these records to ensure that
each patient met the selection criteria. We excluded
people who were not residents of Western Australia
and those with hospital episodes unrelated to ADRs.
There were 37 296 patients who lived andwere treated
in Western Australia and had at least one admission
episode for an ADR. Each patient’s first ADR record
was identified, thereby distinguishing first time from
repeat episodes. We included 28 548 patients with a
first time ADR in 1980-2000 as a cohort and followed
themup for threeyears.The figure shows theprocess of
selecting patients for the study.
Follow-up and outcome measurements
The length of follow-up was the time in days from
hospital separation for the first timeADRepisode (time
zero) to the date of a second separate admission for an
ADR or, in the absence of a repeat event within three
years, to the date of the third anniversary from time
zero or date of death if within three years (censored).
We identified the drugs responsible for first time
ADRs from the E codes on the hospital morbidity data
system. In the3.9%of all instanceswhenmultipledrugs
were thought tobe responsible for anADRwe included
in the analysis only the drug clinically considered to be
primarily responsible. Drugs were grouped into 20
broad categories as defined in ICD-10-AM, with
closest possible equivalent specifications for ICD-9
and ICD-9-CM. Table 1 shows the distributions of
admissions for first timeADRs according to these drug
categories and details themodifications required in the
drug categories caused by differences between ICD-9/
ICD-9-CM and ICD-10-AM. Table 2 gives more
specific details of the top 30 drug groups most often
implicated in first time ADRs at the four digit E code
level (ICD-9/ICD-9-CM) and three digit Y code level
(ICD-10-AM), which accounted for more than 81% of
all episodes in the study.
Comorbidity was measured by using the Charlson
comorbidity index22 conditions mentioned in the
hospital record for the first time ADR, coded to an
ICD-9, ICD-9-CM, or ICD-10-AM rubric that were
different from the principal index diagnosis. Nineteen
fields existedwithin the hospitalmorbidity data system
for recording comorbid conditions. The performance
of the linkage system in adjusting for comorbidty in
longitudinal research designs has been previously
demonstrated.23 24 We calculated the Charlson score
by adding scores assigned to each specific diagnosis,
which was generated using the Dartmouth-Manitoba
algorithms for ICD coded administrative data.25 26
Table 3 shows Charlson comorbid conditions (with
weights) present at the admission for first time ADR.
Weassigneda socioeconomicdisadvantage score for
each patient by transforming residential postcode into
numerical values of the index of relative socioeco-
nomic disadvantage compiled from the 1986, 1991,
1996, and 2001 Australian censuses and applied to
1980-8, 1989-93, 1994-8, and 1999-2003,
respectively.27 The index was developed by the
Table 2 | Top 30 drug groups (ICD E codes) most often implicated in admission for first time
adverse drug reaction (ADR) in 28 548 patients aged ≥60, Western Australia, 1980-2000
Drug groups (as defined in ICD-10-AM) ICD-9/ICD-9-CM ICD-10-AM
No (%) of
patients
Systemic antibiotics:
Penicillins E930.0 Y40.0 881 (3.1)
Unspecified systemic antibiotics E930.9 Y40.9 569 (2.0)
Other systemic antibiotics E930.8 Y40.8 505 (1.8)
Cephalosporins and other β lactams E930.5 Y40.1 353 (1.2)
Hormones (including synthetics and antagonists):
Glucocorticoids and synthetics E932.0 Y42.0 1328 (4.7)
Insulins and oral antidiabetic drugs E932.3 Y42.3 416 (1.5)
Primarily systemic agents:
Antineoplastic/immunosuppressive drugs E933.1/E930.7 Y43.1-4 1980 (6.9)
Agents primarily affecting blood constituents:
Anticoagulants E934.2 Y44.2 1964 (6.9)
Thrombolytic drugs E934.4 Y44.5 247 (0.9)
Analgesics/antipyretics/anti-inflammatory drugs:
NSAIDs and antirheumatics E935.6 Y45.2-4 2026 (7.1)
Opioids and related analgesics E935.2 Y45.0 1388 (4.9)
Salicylates E935.3 Y45.1 442 (1.5)
4-aminophenol derivatives (such as paracetamol) E935.4 Y45.5 361 (1.3)
Antiepileptics and antiparkinsonian drugs:
Hydantoin derivatives E936.1 Y46.2 408 (1.4)
Antiparkinsonian drugs E936.4 Y46.7 359 (1.3)
Other and unspecified antiepileptics E936.3 Y46.6 302 (1.1)
Psychotropic drugs:
Antidepressants E939.0 Y49.0-2 596 (2.1)
Phenothiazine antipsychotics/neuroleptics E939.1 Y49.3 365 (1.3)
Agents primarily affecting cardiovascular system:
Cardiac stimulant glycosides/similar drugs E942.1 Y52.0 1702 (6.0)
Other antihypertensive drugs E942.6 Y52.5 1708 (6.0)
Other antidysrhythmic drugs E942.0 Y52.2 786 (2.8)
Coronary vasodilators E942.4 Y52.3 662 (2.3)
Peripheral vasodilators (ICD-9 sympatholytics) E941.3 Y52.7 269 (0.9)
Agents affecting water balance, mineral/uric acid metabolism:
Loop and other diuretics E944.4 Y54.4-5 1257 (4.4)
Benzothiadiazine derivatives E944.3 Y54.3 322 (1.1)
Uric acid metabolism drugs (such as colchicine) E944.7 Y54.8 242 (0.8)
Agents affecting muscles/respiratory system:
Antiasthmatics (including theophylline) E944.1/E945.7 Y55.6 472 (1.7)
Topical agents affecting skin, eyes, ENT, dental:
Local anti-infectives/anti-inflammatory drugs E946.0 Y56.0 435 (1.5)
Other and unspecified drugs and medicines:
Unspecified drug or medicines E947.9 Y57.9 555 (1.9)
Other drugs or medicines E947.8 Y57.8 354 (1.2)
Total 23 254 (81.5)
ADR=adverse drug reaction; ICD=International Classification of Diseases; NSAIDs=non-steroidal anti-
inflammatory drugs; ENT=ear, nose, throat.
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Australian Bureau of Statistics and consists of four
variables that reflect or measure relative disadvantage,
including low income, low educational attainment,
high unemployment, and low skilled occupation; it has
been used extensively in public health research.27 The
continuous values of the indexes were then partitioned
into fifths.
Statistical analysis
Statistical analysis was performed with SPSS version
12.0.1 (SPSS, Chicago, IL). We used the independent
samples t test for continuous variables and a χ2 test for
categorical variables to compare characteristics
between patients with first time only and repeat ADR
episodes. Variables associated with first time admis-
sions for an ADR were used for univariate and
multivariate analysis. Univariate analysis was under-
taken to screen forpotentially important variables tobe
used in the subsequent multivariate analysis. Multi-
variate Cox proportional hazards regression models
were fitted by using all variables included as main
effects terms, and we performed corresponding linear
trend tests. When assessing each drug category, we
fitted the Cox regression models using deviation
coding, which compared the effect on repeat ADRs
of each first time drug category with the average risk of
all 20 drug categories. We obtained hazard ratios and
associated 95% confidence intervals after adjusting for
age, sex, indigenous status, residential locality, socio-
economic disadvantage, admission type, hospital type,
length of hospital stay, calendar period of ADR,
Charlson comorbidity index, and drug categories.
Other studies have identified these variables as those
influencing the risk of first time ADRs,10-15 and they
were significant predictors of repeat ADRs based on
the preceding univariate analysis. To assess potential
for survival bias, we separately analysed data from all
patients and fromasubset that excluded thosewhodied
in the three year follow-up period.
RESULTS
Results using data from all patients were similar to
those obtainedwhen we excluded patients who died in
the follow-up period.We have therefore reported only
the results from analyses that included all patients.
Within the first three years of follow-up, 5056 patients
(17.7%) experienced a repeat admission for an ADR.
Table 4 presents unadjusted and adjusted hazard ratios
for repeat ADRs for selected characteristics in the
participants. The adjusted hazard ratios for repeat
ADRswere 1.08 (95% confidence interval 1.02 to 1.15)
for men, 0.87 (0.80 to 0.93) for private hospital
admissions, 1.11 (1.05 to 1.18) for length of hospital
stay≥14days, 2.34 (2.00 to 2.73) for admission in 1995-
9comparedwith theearliest timeperiod, and1.71 (1.46
to 1.99) for a Charlson comorbidity index score ≥7,
with a significant linear trend across quantitative or
ordinal quantitative variables. Residential location in
the metropolitan area (1.10, 1.01 to 1.19) was margin-
ally significant (P=0.03). Therewas no significant effect
on repeat ADRs for age, indigenous status, type of
admission, and socioeconomic disadvantage.
Table 5 shows the effects of individual Charlson
comorbid conditions on repeatADRs.Comparedwith
patients who had no recorded comorbidity, the
analysis identified sizeable adjusted hazard ratios for
congestive cardiac failure (1.56, 1.43 to 1.71), periph-
eral vascular disease (1.27, 1.09 to 1.48), chronic
pulmonary disease (1.61, 1.45 to 1.79), rheumatologi-
cal disease (1.65, 1.41 to 1.92), mild liver disease (1.48,
1.05 to 2.07), mild to moderate diabetes (1.18, 1.07 to
1.30), diabetes with chronic complications (1.91, 1.65
to 2.22), renal disease (1.93, 1.71 to 2.17), any
malignancy including lymphoma and leukaemia
(1.87, 1.68 to 2.09), moderate to severe liver disease
(1.85, 1.18 to 2.92), and metastatic solid tumour (2.25,
1.92 to 2.64). Cerebrovascular disease (0.85, 0.73 to
0.98), dementia (0.62, 0.49 to 0.78), and hemiplegia or
paraplegia (0.73, 0.59 to 0.89) were apparently
preventive for repeat ADRs. There was no significant
relation formyocardial infarction, peptic ulcer disease,
or AIDS, although people with AIDS had only two
repeat ADRs.
Table 6 shows the effect of each drug category (as
defined in ICD-10-AM) responsible for first time
ADRs. Three drug categories were associated with a
greater than average risk of repeatADRs,with adjusted
hazard ratios of 1.51 (1.34 to 1.69) for hormones, 2.12
(1.89 to 2.38) for primarily systemic agents (including
antineoplastics, immunosuppressives, and anti-
neoplastic antibiotics), and 4.06 (2.00 to 8.26) for
bacterial vaccines. The latter category, however, had
low counts for first time and repeat ADRs.
DISCUSSION
Predictive factors for repeat ADR admission
In this population based cohort study of factors that
predict repeat admission for ADRs in older adults we
Table 3 | Charlson comorbidity conditions (with weights) present at admission for first time
adverse drug reaction (ADR) in 28 548 patients aged ≥60, Western Australia, 1980-2000
Charlson comorbid conditions Weight No (%) of patients
Myocardial infarction 1 1556 (5.5)
Congestive cardiac failure 1 4745 (16.6)
Peripheral vascular disease 1 1174 (4.1)
Cerebrovascular disease 1 1827 (6.4)
Dementia 1 868 (3.0)
Chronic pulmonary disease 1 2034 (7.1)
Rheumatological disease 1 832 (2.9)
Peptic ulcer disease 1 2145 (7.5)
Mild liver disease 1 199 (0.7)
Diabetes (mild to moderate) 1 2807 (9.8)
Diabetes with complications 2 755 (2.6)
Hemiplegia or paraplegia 2 864 (3.0)
Renal disease 2 1418 (5.0)
Any malignancy, including lymphoma/leukaemia 2 3349 (11.7)
Moderate or severe liver disease 3 108 (0.4)
Metastatic solid tumour 6 1518 (5.3)
AIDS 6 5 (0.0)
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found strong evidence that comorbidity from chronic
disease rather thanadvancing age increases their rate of
repeat ADRs. Comorbid congestive cardiac failure,
diabetes, and peripheral vascular, chronic pulmonary,
rheumatological, hepatic, renal, and malignant dis-
eases were all strong predictors of readmissions for
ADRs.Our results were consistentwith those of earlier
studies that a higher Charlson comorbidity index
score,4 renal insufficiency,28 and diabetes29 were all risk
factors for first time ADRs. We also found that
comorbid cerebrovascular disease, dementia, and
hemiplegia or paraplegia were associated with a
Table 4 | Unadjusted and adjusted hazard ratios (with 95% confidence intervals) of repeat adverse drug reaction (ADRs) for
selected characteristics in older adults
Characteristics at first
admission for ADR
First time ADR
only (n=23 492)
Repeat ADR
(n=5056)
Unadjusted Adjusted
HR (95% CI) P value* HR (95% CI)† P value*
Age at admission (years):
60-64 3226 790 1.00‡
0.18
1.00‡
0.39
65-69 3830 870 0.96 (0.87 to 1.05) 0.97 (0.88 to 1.07)
70-74 4697 982 0.90 (0.82 to 0.99) 0.93 (0.84 to 1.02)
75-79 4647 1009 0.95 (0.86 to 1.04) 0.99 (0.91 to 1.10)
≥80 7092 1405 0.92 (0.84 to 1.00) 0.96 (0.87 to 1.05)
Sex:
Female 13 264 2810 1.00‡
<0.001
1.00‡
<0.01
Male 10 228 2246 1.13 (1.07 to 1.19) 1.08 (1.02 to 1.15)
Indigenous status:
Non-Aboriginal/TSI 23 288 5006 1.00‡
0.34
1.00‡
0.85
Aboriginal/TSI 204 50 1.15 (0.87 to 1.52) 1.03 (0.77 to 1.37)
Residential locality:
Regional/rural area 3936 847 1.00‡
0.53
1.00‡
0.03
Metropolitan Perth 19 556 4209 1.02 (0.95 to 1.10) 1.10 (1.01 to 1.19)
Admission type:
Elective 6469 1405 1.00‡
0.75
1.00‡
0.13
Emergency 17 007 3648 1.01 (0.95 to 1.07) 1.05 (0.99 to 1.12)
Type of hospital attended:
Public 19 542 4063 1.00‡
<0.001
1.00
<0.001Private 3275 930 1.32 (1.23 to 1.42) 0.87 (0.80 to 0.93)
Other 675 63 0.41 (0.32 to 0.53) 0.80 (0.61 to 1.04)
Length of hospital stay (days):
<14 15 803 3408 1.00‡
<0.001
1.00‡
0.001
≥14 7689 1648 1.14 (1.08 to 1.21) 1.11 (1.05 to 1.18)
Socioeconomic disadvantage (fifths):
1 (most) 4671 982 1.00‡
<0.001
1.00‡
0.15
2 5495 1055 0.92 (0.85 to 1.01) 0.90 (0.83 to 0.99)
3 3184 710 1.05 (0.96 to 1.16) 0.99 (0.90 to 1.09)
4 3365 733 1.04 (0.95 to 1.15) 0.95 (0.86 to 1.04)
5 (least) 6752 1575 1.11 (1.02 to 1.20) 0.94 (0.87 to 1.02)
Calendar period of ADR:
1980-4 2097 183 1.00‡
<0.001
1.00‡
<0.001
1985-9 3540 459 1.48 (1.25 to 1.76) 1.44 (1.21 to 1.72)
1990-4 5915 780 1.53 (1.31 to 1.80) 1.52 (1.29 to 1.79)
1995-9 9409 1946 2.37 (2.03 to 2.75) 2.34 (2.00 to 2.73)
Charlson comorbidity index score:
0 9511 1719 1.00‡
<0.001
1.00‡
<0.001
1-2 10 220 2396 1.46 (1.38 to 1.56) 1.30 (1.22 to 1.38)
3-4 2262 579 1.86 (1.69 to 2.04) 1.42 (1.29 to 1.57)
5-6 563 151 2.82 (2.38 to 3.33) 2.04 (1.72 to 2.42)
≥7 936 211 3.10 (2.68 to 3.58) 1.71 (1.46 to 1.99)
TSI=Torres Strait Islander.
*Test for trend or standard P value across quantitative or ordinal quantitative variables.
†Estimates from Cox regression model included terms for age (continuous), sex (female, male), indigenous status (non-Aboriginal, Aboriginal),
residence (regional/rural area, metropolitan), admission type (elective, emergency), type of hospital attended (public, private, other), length of stay
(continuous), socioeconomic disadvantage (fifths), calendar period of ADR (continuous), Charlson comorbidity index score (continuous), and drug
categories responsible for first time ADR.
‡Reference category.
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reduced risk of repeat admission for ADRs. First
admission for an ADR with a longer hospital stay,
admissions in the most recent time period, and male
sex also predicted repeat ADR admissions, with
admission to private hospitals showing a reduced risk.
ADRs are acknowledged as a major health problem
in older people.1-7 30 A meta-analysis of 68 observa-
tional studies reported that the proportion of admis-
sions related to ADRs in older people was four times
higher than in younger people.31 We found, however,
that advancing agewas not independently predictive of
repeat admissions related to ADRs in people ≥60. This
is consistent with results from previous studies that
have examined the independent effects of age on first
timeADRs.11 13Other reported risk factors for first time
ADRs include sex, multiple drug regimens, inap-
propriate use of drugs, alcohol intake, cognitive
function, and depression.4 10-15 To our knowledge,
however, the same risk factors for repeat ADRs have
not been previously investigated.
Strengths and limitations
There are several potential explanations for the
observed importance of comorbidity. Comorbidity
might increase vulnerability to ADRs by impairing
body systems—for example, cardiovascular, pulmon-
ary, renal, and hepatic insufficiency can cause changes
in pharmacokinetics and pharmacodynamics.28 There
might be increased opportunity for drug interactions
because of polypharmacy for multiple morbidities.
Finally, Berkson’s bias—that is, ADRs are more likely
to be identified and diagnosed because of comorbid
conditions increasingaperson’s contactwith thehealth
system.32 A reduced risk of repeat ADRs associated
with admission to private hospital might be explained
by private patients having generally better health or
being socioeconomically advantaged and having
stronger social supports. This latter theory, however,
is inconsistent with the direct measure of least socio-
economic disadvantage used in this study, which had
no effect (hazard ratio 0.94, 0.87 to 1.02).
An important limitation of the studywas the absence
of data in thehospitalmorbiditydata systemon specific
drug doses and multiple drug regimens. Nevertheless,
we did have information on the drug category
primarily responsible forADRs.We assessed the effect
of each drug category by comparing it with the average
risk of a repeat ADR from the 20 drug categories
responsible for first time ADRs. Hormones, primarily
systemic agents, and bacterial vaccineswere associated
with higher than average risks of repeatADR, although
the numbers in the bacterial vaccines group was small.
The higher risk of repeat ADRs from hormones and
primarily systemic agents (which include anti-
neoplastic drugs) was expected as severe side effects
of these drugs are well known. We examined the
diagnoses in patients who had first time ADRs caused
by bacterial vaccines and found that nearly 38% of
these patients had malignant diseases treated with
bacillus Calmette-Guerin (BCG) vaccine or other
vaccine based immunotherapy. Hence, the increased
effect on repeat ADRs observed in the category of
bacterial vaccines was probably caused by the con-
comitant use of antineoplastic agents (part of “primar-
ily systemic agents”). The age standardised rates of all
cancers for males and females in 2005 were 356.1 and
260.9 per 100 000 person years, based on a publication
from the Western Australia cancer registry.33 Hence,
men have a higher incidence of cancer than women in
Western Australia, which might explain the observed
higher risk of repeat ADRs in men.
The risk of adverse drug effects might increase with
increasing drug dose. Although we did not have
specific data on drug dose for individuals in our
population dataset, we investigated the extent to which
doses were prescribed within the normal limits set by
the manufacturers as documented in the Monthly
Index of Medical Specialities (MIMS-Australia), a
database containing approved product information
from manufacturers for medicines used in Australia.34
We obtained data on pharmacy dispensing of drugs for
discharge and outpatients for the year 2000 from the
Table 5 | Adjusted hazard ratios (HR) with 95% confidence intervals for repeat adverse drug
reactions (ADRs) for Charlson comorbidity at first admission to hospital for ADR in older adults
Comorbid conditions
No (%) with first
time ADR only
No (%) with
repeat ADR
Adjusted HR
(95% CI)* P value†
Congestive cardiac failure 3858 (16.4) 889 (17.6) 1.56 (1.43 to
1.71)
<0.001
Peripheral vascular disease 978 (4.2) 196 (3.9) 1.27 (1.09 to
1.48)
<0.01
Chronic pulmonary disease 1537 (6.5) 497 (9.8) 1.61 (1.45 to
1.79)
<0.001
Rheumatological disease 622 (2.6) 210 (4.2) 1.65 (1.41 to
1.92)
<0.001
Mild liver disease 164 (0.7) 35 (0.7) 1.48 (1.05 to
2.07)
0.03
Diabetes (mild to moderate) 2276 (9.7) 531 (10.5) 1.18 (1.07 to
1.30)
<0.01
Diabetes with chronic complications 507 (2.2) 248 (4.9) 1.91 (1.65 to
2.22)
<0.001
Renal disease 1045 (4.4) 373 (7.4) 1.93 (1.71 to
2.17)
<0.001
Any malignancy including lymphoma
and leukaemia
2538 (10.8) 811 (16.0) 1.87 (1.68 to
2.09)
<0.001
Moderate or severe liver disease 89 (0.4) 19 (0.4) 1.85 (1.18 to
2.92)
<0.01
Metastatic solid tumour 1245 (5.3) 273 (5.4) 2.25 (1.92 to
2.64)
<0.001
Cerebrovascular disease 1601 (6.8) 226 (4.5) 0.85 (0.73 to
0.98)
0.02
Dementia 791 (3.4) 77 (1.5) 0.62 (0.49 to
0.78)
<0.001
Hemiplegia or paraplegia 762 (3.2) 102 (2.0) 0.73 (0.59 to
0.89)
<0.01
Myocardial infarction 1332 (5.7) 224 (4.4) 0.98 (0.84 to
1.13)
0.73
Peptic ulcer disease 1847 (7.9) 298 (5.9) 1.09 (0.95 to
1.25)
0.24
AIDS 3 (<0.1) 2 (<0.1) 1.65 (0.41 to
6.71)
0.48
*Estimates from Cox regression models included terms for age (continuous), sex (female, male), indigenous
status (non-Aboriginal, Aboriginal), residence (regional/rural area, metropolitan), admission type (elective,
emergency), type of hospital attended (public, private, other), length of stay (continuous), socioeconomic
disadvantage (fifths), calendar period of ADR (continuous), and drug categories responsible for first-time ADR.
†For hazard ratio (HR), using patients with absent comorbidity as reference category.
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pharmacy department of one of the teaching hospitals
in Western Australia. Analysis of prescribed doses for
these drugs showed that nearly all (99.6%) were within
the range recommended by the manufacturer as
recorded in MIMS Australia.34
The strengths of our study include the cohort design
with population based and audited data of high
quality,17 thus overcoming issues related to selection
and recall biases as well as loss to follow-up. Loss to
follow-up would have been small as interstate migra-
tion occurred in only 3.5% of residents in Western
Australia during the 24 year study period.35 The
longitudinal linked data allowed us to identify repeat
ADRs in the same patient regardless of changes in the
treating hospital. The fact that death records were
linked to 69%of participantswas consistent with a high
level of completeness of follow-up. An important
limitation of the study was that the administrative
hospital morbidity data system is known to code only
60%of the17Charlsoncomorbidconditions relative to
information obtained from chart review.23 False
positive diagnoses of comorbid conditions, however,
are infrequent for most conditions (range 0-1.5%).23
Although underascertainment of comorbidity is an
issue in this study, it seems implausible that the levels of
underascertainment would differ substantially
between patients with first time ADR only and those
with repeat ADRs. Another limitation was that the
study focusedonlyonADRs that either causedhospital
admission or extended hospital stay, whereas most
ADRs (90%) are fairly minor and occur in the
community without admission to hospital.36 ADRs
resulting in admission, however, represent the most
severeadverse sideeffectsofmedicationuseand lead to
considerable morbidity and financial costs. They are
thus arguably the most appropriate object of analysis.
As with other studies of this nature, reliability of
ascertainment might vary because the presence and
diagnosis of an ADR is subject to clinical judgment.
The diagnosis of an ADRwas made by senior hospital
doctors (consultants and registrars) and junior doctors
recorded them in text on a structured hospital
separation abstract. This step in the processwas subject
to diagnostic error at a level that is usual in clinical
practice. The second step in the process involved
coding the text, including external causes or contribut-
ing factors, using the ICD-9, ICD-9-CM, or ICD-10-
AM coding manuals (for different time periods). This
was performed in each of the hospitals by qualified
clinical coders who are trained in the use of the ICD
codes and were able to obtain additional information
from the medical notes as required. The accuracy of
Table 6 | Adjusted hazard ratios (with 95% confidence intervals) of repeat adverse drug reactions (ADRs) for primary drug
category responsible for first time ADRs in older adults
Drug category*
No (%) with
first time
ADR only No (%) with repeat ADR Adjusted HR (95% CI)† P value‡
E930/Y40 Systemic antibiotics§ 2249 (9.6) 423 (8.4) 0.81 (0.45 to 1.50) 0.53
E931/Y41 Other systemic anti-infectives/antiparasitics 365 (1.6) 65 (1.3) 1.02 (0.80 to 1.30) 0.89
E932/Y42Hormones (including synthetic and antagonists) 1649 (7.0) 525 (10.4) 1.51 (1.34 to 1.69) <0.001
E933/Y43 Primarily systemic agents 1456 (6.2) 666 (13.2) 2.12 (1.89 to 2.38) <0.001
E934/Y44 Agents primarily affecting blood constituents 1980 (8.4) 452 (8.9) 0.93 (0.82 to 1.05) 0.23
E935/Y45 Analgesics/antipyretics/anti-inflammatory
drugs
4006 (17.1) 688 (13.6) 0.76 (0.68 to 0.84) <0.001
E936/Y46 Antiepileptics/antiparkinsonian drugs 903 (3.8) 218 (4.3) 1.13 (0.97 to 1.32) 0.12
E937/Y47 Sedatives, hypnotics, antianxiety drugs 356 (1.5) 50 (1.0) 0.74 (0.56 to 0.97) 0.03
E938/Y48 Anaesthetics, therapeutic gases 372 (1.6) 42 (0.8) 0.52 (0.39 to 0.71) <0.001
E939/Y49 Psychotropic drugs§ 1266 (5.4) 268 (5.3) 0.96 (0.83 to 1.11) 0.56
E940/Y50 Central nervous system stimulants 15 (0.1) 3 (0.1) 0.76 (0.26 to 2.22) 0.61
E941/Y51 Drugs primarily affecting autonomic nervous
system§
377 (1.6) 99 (2.0) 0.87 (0.71 to 1.07) 0.18
E942/Y52Agentsprimarily affectingcardiovascular system 4702 (20.0) 874 (17.3) 0.93 (0.84 to 1.04) 0.21
E943/Y53 Agents primarily affecting gastrointestinal
system
220 (0.9) 32 (0.6) 0.64 (0.46 to 0.90) 0.01
E944/Y54 Agents affecting water balance/minerals/uric
acid metabolism§
1703 (7.2) 321 (6.4) 0.99 (0.86 to 1.13) 0.96
E945/Y55 Agents affecting muscle/respiratory system 490 (2.1) 73 (1.4) 1.01 (0.80 to 1.27) 0.96
E946/Y56 Topical agents affecting skin, ENT, dental 496 (2.1) 81 (1.6) 0.86 (0.69 to 1.07) 0.18
E947/Y57 Other and unspecified drugs and medicines 824 (3.5) 158 (3.1) 1.02 (0.86 to 1.21) 0.80
E948/Y58 Bacterial vaccines 9 (<0.1) 7 (0.1) 4.06 (2.00 to 8.26) <0.001
E949/Y59 Other and unspecified vaccines/biologicals 54 (0.2) 11 (0.2) 0.96 (0.54 to 1.69) 0.88
*See table 1 for more explicit specifications of ICD-9/ICD-9-CM and ICD-10-CM code definitions.
†Estimates from Cox regression model included terms for age (continuous), sex (female, male), indigenous status (non-Aboriginal, Aboriginal),
residence (regional/rural area, metropolitan), admission type (elective, emergency), type of hospital attended (public, private, other), length of stay
(continuous), socioeconomic disadvantage (fifths), calendar period of ADR (continuous), and Charlson comorbidity index score (continuous).
‡P value for each drug category responsible for first time ADR compared with overall effect of drug categories.
§See table 1 for details of modification in drug category between coding systems.
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clinical coding (includingE codes) is routinely checked
by coding supervisors as well as by random internal
audits.
We found that older adults who experienced an
ADRduring themost recent study period, 1995-9, had
a 2.4-fold greater risk of recurrence than their counter-
parts in 1980-4. As the studywas longitudinal, we need
to consider the influence of factors that changed with
time. The results are consistent with national drug
consumption data that showed an increase in drug
exposure in older Australians of 4.7% during 2000-1
alone.37 This increase greatly exceeded population
growth, suggestingeither a largerpopulationat riskor a
higher average level of drug exposure per patient. Our
results, derived frompopulation level data, suggest that
there exists a strong temporal correlation between
repeat ADRs in older adults and greater use of drugs in
the community generally.30 38While efforts to improve
the coding of ADRs in hospital morbidity data systems
during the observation period might have contributed
to someof theobservedrise in admissions forADRs, an
earlier validation study inWesternAustralia, involving
a review of hospital charts, found a real increase in
hospital morbidity caused by ADRs from 1980 to
1991.39
Conclusions
This population based cohort study found that
comorbidity and not advancing age predicted repeat
admission for ADRs in patients aged over 60.
Comorbid congestive cardiac failure, peripheral vas-
cular, chronic pulmonary, rheumatological, hepatic,
renal, and malignant diseases, and diabetes were the
comorbid conditions most likely to predict readmis-
sion for ADRs from the therapeutic use of drugs. An
apparent preventive effect was observed with comor-
bid cerebrovascular disease, dementia, and hemiplegia
or paraplegia, possibly because such patients are under
more consistent healthcare supervision. Careful and
frequentmonitoring of prescribeddrugs in older adults
with at risk comorbidities might prevent readmissions
for ADRs. Evaluation of monitoring programmes
delivered by local pharmacists, community nurses,
and general practitioners might be the next step
towards prevention.
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